Microbix Launches Oncology Test Controls
Company Announcements

Microbix Launches Oncology Test Controls

Microbix Biosystms (TSE:MBX) has released an update.

Microbix Biosystems Inc. has introduced Quality Assessment Products (QAPs™) designed to enhance the quality control of histology and PCR-based tests for HPV-related Head and Neck cancer. Presented at EUROGIN 2024, these innovative QAPs are the first standardized slides to improve diagnostic accuracy and reliability across laboratories. The company’s expansion into oncology test controls meets a growing demand in the cancer diagnostics market, projected to exceed a 10% annual growth rate.

For further insights into TSE:MBX stock, check out TipRanks’ Stock Analysis page.

Related Articles
TipRanks Canadian Auto-Generated NewsdeskMicrobix Enhances HPV Testing with New Validation
TipRanks Canadian Auto-Generated NewsdeskMicrobix Unveils Novel HSV Diagnosis Enhancement
TipRanks Canadian Auto-Generated NewsdeskMicrobix Secures Key EU Accreditations for QAPs
Looking for investment ideas? Subscribe to our Smart Investor newsletter for weekly expert stock picks!
Get real-time notifications on news & analysis, curated for your stock watchlist. Download the TipRanks app today! Get the App